Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT01000896

Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel

A Phase I, Open-Label, Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD0530 in Combination With Carboplatin and Paclitaxel Chemotherapy in Japanese Patients With Advanced Solid Malignancies

Status
Withdrawn
Phase
Phase 1
Study type
Interventional
Enrollment
27 (estimated)
Sponsor
AstraZeneca · Industry
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

The primary purpose of this study is to explore the safety and tolerability of AZD0530 in combination with carboplatin and paclitaxel in Japanese patients with non small cell lung cancer and epithelial ovarian cancer.

Conditions

Interventions

TypeNameDescription
DRUGAZD0530film coated tablet, PO, daily
DRUGCarboplatinintravenous, 3 weeks
DRUGpaclitaxelintravenous, 3 weeks

Timeline

Start date
2010-01-01
Primary completion
2010-09-01
Completion
2011-03-01
First posted
2009-10-23
Last updated
2010-02-04

Locations

2 sites across 1 country: Japan

Source: ClinicalTrials.gov record NCT01000896. Inclusion in this directory is not an endorsement.